Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Barbara Holzer, Broadcast Manager
w. (202) 588-7716
bholzer@citizen.org

Karilyn Gower, Press Officer
w. (202) 588-7779
kgower@citizen.org

Ben Somberg, Press Officer (regulatory matters)
w. (202) 588-7742
bsomberg@citizen.org, Twitter

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog
Facebook/publiccitizen

Follow us on Twitter

 

Dec. 21, 2012

Public Citizen Urges FDA to Reject Accelerated Approval for Possibly Dangerous Anti-TB Drug Bedaquiline

Phase 2 Trials Showed Alarmingly Increased Risk of Death

WASHINGTON, D.C. – U.S. Food and Drug Administration (FDA) officials should not approve the anti-tuberculosis drug bedaquiline, because clinical trials showed the drug could be highly dangerous, Public Citizen said today in a letter to the agency.

In the letter, Public Citizen said it strongly opposes the accelerated approval of bedaquiline because patients taking the drug in addition to standard TB treatment during a phase 2 clinical trial were five times likelier to die than those who took a placebo.

“In the face of clinical evidence of increased deaths, including deaths from TB or TB-related causes in patients getting bedaquiline, compared to those getting a placebo, it is not possible to give accelerated approval to the drug,” the letter stated.

In light of the increased possibility for death and the need to deny accelerated approval, Public Citizen said the FDA should consider if future phase 3 trials would be ethical and urged the FDA to confirm the following:

- All institutional review boards (IRBs) that are reviewing the phase 3 trial plans have been provided with the mortality data from the phase 2 trial and have assessed if the risks of the research outweigh the potential benefits;

- All subjects already enrolled in the phase 3 trial have been informed of the mortality data from the phase 2 trial; and

- The IRB-approved informed consent documents for the phase 3 trial clearly describe the mortality data from the phase 2 trial.

The letter also criticized the FDA for even considering the drug for approval at this stage of testing. The fact that bedaquiline is part of a new class of drug means that an increased level of scrutiny should be required for its approval. But the FDA had not yet answered concerns related to unexplained increases in toxicity and death in patients getting the drug, a common question in new drug classes, even though it has admitted that the drug could be the culprit.

To read the letter, visit http://www.citizen.org/hrg2088.
 

Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.